Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph Aquila

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
The Journal of Clinical Psychiatry|March 27, 2002
Management of weight gain in patients with schizophreniaRalph Aquila
Health Affairs (Project Hope)|May 8, 2018
Behavioral Health HomesRalph Aquila
CNS Spectrums|December 20, 2015
Cognitive impairment in schizophrenia: the great unmet needRalph Aquila, Leslie Citrome
Primary Care Companion to the Journal of Clinical Psychiatry|March 12, 2004
Interventions for Weight Gain in Adults Treated With Novel AntipsychoticsRalph Aquila, Marianne Emanuel
Psychiatric Services (Washington, D.C.)|April 6, 2012
Fountain house and recovery centersKenneth J Dudek, Ralph Aquila
Medgenmed : Medscape General Medicine|April 5, 2007
The store front, Fountain House, and the rehabilitation allianceRalph Aquila, Thomas J Malamud, Thomas Sweet, et al.
Journal of Psychosocial Rehabilitation and Mental Health|November 1, 2021
Clubhouses as Essential Communities During the COVID-19 PandemicLiza Hinchey, Amber Michon, Jessica Drews, et al.
CNS Spectrums|August 16, 2018
Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophreniaHenry A Nasrallah, Ralph Aquila, Yangchun Du, et al.
Psychopharmacology Bulletin|August 26, 2017
Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole LauroxilHenry A Nasrallah, Ralph Aquila, Arielle D Stanford, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 22, 2006
Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trialSandra L Tunis, Douglas E Faries, Allen W Nyhuis, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
The Journal of Clinical Psychiatry|March 27, 2002
Management of weight gain in patients with schizophreniaRalph Aquila
Health Affairs (Project Hope)|May 8, 2018
Behavioral Health HomesRalph Aquila
CNS Spectrums|December 20, 2015
Cognitive impairment in schizophrenia: the great unmet needRalph Aquila, Leslie Citrome
Primary Care Companion to the Journal of Clinical Psychiatry|March 12, 2004
Interventions for Weight Gain in Adults Treated With Novel AntipsychoticsRalph Aquila, Marianne Emanuel
Psychiatric Services (Washington, D.C.)|April 6, 2012
Fountain house and recovery centersKenneth J Dudek, Ralph Aquila
Medgenmed : Medscape General Medicine|April 5, 2007
The store front, Fountain House, and the rehabilitation allianceRalph Aquila, Thomas J Malamud, Thomas Sweet, et al.
Journal of Psychosocial Rehabilitation and Mental Health|November 1, 2021
Clubhouses as Essential Communities During the COVID-19 PandemicLiza Hinchey, Amber Michon, Jessica Drews, et al.
CNS Spectrums|August 16, 2018
Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophreniaHenry A Nasrallah, Ralph Aquila, Yangchun Du, et al.
Psychopharmacology Bulletin|August 26, 2017
Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole LauroxilHenry A Nasrallah, Ralph Aquila, Arielle D Stanford, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 22, 2006
Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trialSandra L Tunis, Douglas E Faries, Allen W Nyhuis, et al.
Pageof 2